Mankind Pharma Ltd
NSE:MANKIND
Mankind Pharma Ltd
Income from Continuing Operations
Mankind Pharma Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Income from Continuing Operations
₹19.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹54.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹50B
|
CAGR 3-Years
24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹114.9B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
7%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Income from Continuing Operations
₹28.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹18.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
Mankind Pharma Ltd
Glance View
Mankind Pharma Ltd. has carved a unique niche in the pharmaceutical landscape of India, emerging as a formidable entity through an intriguing blend of affordability and accessibility. Founded in 1995 by R. C. Juneja, the company has steadily grown its portfolio to encompass a vast range of pharmaceutical products spanning prescription medications, over-the-counter (OTC) drugs, and consumer healthcare goods. Operating with a distinctive business model rooted in the ethos of delivering quality medicine at affordable prices, Mankind Pharma reaches deep into the densely populated tier II and tier III cities of India, ensuring that healthcare is accessible to the masses who need it the most. This strategic outreach, coupled with strong marketing and distribution networks, serves as a cornerstone of its business success. The company’s financial health is buoyed by its diversified product range, which caters to multiple therapeutic areas including antibiotics, cardiovascular, antifungal, and gastrointestinal, among others. Their robust R&D initiatives further reinforce their competitive edge, enabling them to continually introduce new and effective products that resonate with both healthcare providers and consumers. Revenue streams are not just confined to domestic borders; Mankind Pharma has been expanding its footprint internationally, penetrating markets across Asia, Africa, and the Americas. By striking a strategic balance between volume-driven pricing models and extensive market reach, Mankind Pharma not only emphasizes profitability but also solidifies its commitment to public health initiatives globally, thus creating a sustainable and progressive business trajectory.
See Also
What is Mankind Pharma Ltd's Income from Continuing Operations?
Income from Continuing Operations
19.4B
INR
Based on the financial report for Mar 31, 2024, Mankind Pharma Ltd's Income from Continuing Operations amounts to 19.4B INR.
What is Mankind Pharma Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
15%
Over the last year, the Income from Continuing Operations growth was 48%. The average annual Income from Continuing Operations growth rates for Mankind Pharma Ltd have been 15% over the past three years .
You don't have any saved screeners yet